The news directly pertains to AnaptysBio as the analyst from Wedbush has maintained a Neutral rating on the company and lowered the price target. This could potentially impact the stock's performance in the short term as investors adjust their expectations based on the new price target. However, the Neutral rating suggests that the analyst does not expect significant changes in the stock's price direction.